Compare CLLS & CAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLLS | CAII |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 337.6M |
| IPO Year | 2014 | 2026 |
| Metric | CLLS | CAII |
|---|---|---|
| Price | $3.40 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 74.7K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.35 | $9.90 |
| 52 Week High | $5.48 | $9.98 |
| Indicator | CLLS | CAII |
|---|---|---|
| Relative Strength Index (RSI) | 68.24 | 74.11 |
| Support Level | $3.41 | $9.92 |
| Resistance Level | $4.24 | N/A |
| Average True Range (ATR) | 0.18 | 0.01 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 99.12 | 75.00 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Collective Acquisition Corp II is a blank check company.